Wall Street Signals: JZZ Technologies, Inc. Signs LOI to Acquire Life Factor Research Inc

JZZ Technologies, Inc. Signs LOI to Acquire Life Factor Research Inc

In its second acquisition in the bioscience and human longevity sector, JZZ Technologies, Inc. intends to acquire Life Factor Research Inc. and begin marketing its unique and patented line of natural supplements

JZZ Technologies, Inc., (OTC Pink: JZZI) has signed a Letter of Intent ("LOI") with life sciences company Life Factor Research Inc. of Medford, Oregon. Under the terms of the Letter of Intent, dated November 30, 2021, JZZ Technologies, Inc. will acquire 100% ownership of Life Factor Research Inc., its formulations, research, products, and manufacturing operations.

Life Factor Research Inc. is comprised of seasoned professionals dedicated to combining proven science with the very best that nature provides to create products that change lives. Their team has dedicated their professional lives to the creation, testing, and implementing of technologies - many of which are used by some of the most reputable Pharmaceutical and Nutraceutical companies in existence.

Life Factor Research's products focus on two groups: proprietary formulations and bioavailability technology. These two areas form the seedbed for the company's proprietary and patented products that deal with testosterone support, prostate support, restorative sleep, type II diabetes, and metabolic syndrome, pain analgesics, gluten sensitivity, adaptogens, and skin stem cell formulations. Several of the company's leading products are sold commercially under the Natures Balance brand name.

The new agreement also contemplates that Charles Layton and his team of researchers and scientists will continue to operate all aspects of Life Factor Research as a wholly-owned subsidiary of JZZ Technologies, Inc. Mr. Layton has a considerable history in the life sciences field and will assume the role as head of JZZ Technologies' life sciences and biotechnology operations.

Charles Layton, CEO Of Life Factor Research Inc., stated, "This acquisition is well-timed for Life Factor Research Inc. and will provide important parts to our marketing, distribution, and access to greater capital. We look forward to the new opportunities that this will create going forward and putting Life Factor Research on a global scale with our much-needed approaches and the products that they foster."

Charles Cardona, CEO of JZZ Technologies, Inc., stated, "Life Factor Research's ongoing development of products and research are an excellent fit for our direction in the life extension and biosciences. We also join with Charles Layton, who can bring his vast experience to our team and head up our life sciences and bioscience operations. This adds a huge resource to our company."

JZZ Technologies intends to provide certain working capital to Life Factor Research, whereby the two parties may achieve and initiate new products, marketing, influencer campaigns, and sales to move the venture into global commercial viability.

About Life Factor Research Inc.

Life Factor Research Inc. is a private company based in Medford, Oregon. Its ongoing development of new ranges of natural extracts to enhance health has enabled the company to develop an entirely new range of never-seen-before nutraceuticals for various medical ailments, immune boost, and human life extension.

About JZZ Technologies, Inc.

JZZ Technologies, Inc. is a diversified technology company engaged in the following two distinct business sectors: (i) its digital media business, which includes online media and apps (activelifestylemedia.com), content creation, digital marketing, streaming video content, publishing, and free over-the-air television (EyeOnTV) targeted to active adults 55+, and; (ii) strategic biotechnology and bioscience-related to Human Life Extension and Human Longevity that can be immediately leveraged to support improved quality of life for the senior population.

JZZ Technologies, Inc.
Charles Cardona, CEO

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106686